Clinical Trials Logo
  1. Home
  2. Advanced Refractory Solid Tumors
  3. NCT04200404

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors Clinical Trial

Official title:
A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Clinical Trial Summary

This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers. There will be a dose escalation portion in "allcomers"to find a suitable dose of regorafenib for combination use with CS1001. This study will also enroll participants with specific tumor types in the phase II part of the study to assess the efficacy, pharmacokinetics and safety of the combined regimen (RP2D of regorafenib + CS 1001)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04200404
Study type Interventional
Source CStone Pharmaceuticals
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 13, 2019
Completion date August 18, 2021
View Details
See also
  Status Clinical Trial Phase
Suspended NCT01762410 - Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors Phase 1
Completed NCT03349073 - An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors Phase 1
Terminated NCT03195764 - Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors Phase 1
Recruiting NCT04892498 - Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) Phase 2
Recruiting NCT05035745 - Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) Phase 1/Phase 2
Recruiting NCT03863145 - Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors Early Phase 1
Active, not recruiting NCT04685473 - Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors Phase 1
Completed NCT04324372 - Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors Phase 1
Recruiting NCT02300467 - NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors Phase 1
Suspended NCT01779336 - Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors Phase 1